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Significant progress has been made over the last decade
towards realizing the potential of natural killer (NK)
cells for cancer immunotherapy. NK cells can respond
rapidly to transformed and stressed cells, and have the
intrinsic potential to extravasate and reach their targets
in almost all body tissues. In addition to donor-derived
primary NK cells, also continuously expanding cytotoxic
cell lines such as NK-92 are being considered for adop-
tive cancer immunotherapy. High cytotoxicity of NK-92
has previously been shown against malignant cells of
hematologic origin in preclinical studies, and general
safety of infusion of NK-92 cells has been established in
phase I clinical trials. To enhance their therapeutic
utility, we genetically modified NK-92 cells to express
chimeric antigen receptors (CAR) specific for tumor-
associated surface antigens. Such CAR were composed
of a tumor-specific scFv antibody fragment fused via
hinge and transmembrane domains to intracellular
signaling moieties such as CD3 zeta chain, or composite
fusion molecules also containing a costimulatory protein
domain in addition to CD3 zeta. For development
towards clinical applications, here a codon-optimized
second generation CAR was constructed that consists of
an ErbB2-specific scFv antibody domain fused via a linker
to a composite CD28-CD3 zeta signaling domain. GMP-
compliant protocols for vector production, lentiviral
transduction and expansion of a genetically modified
NK-92 single cell clone (NK-92/5.28.z) were established.
Functional analysis of NK-92/5.28.z cells revealed high
and stable CAR expression, selective cytotoxicity against
ErbB2-expressing but otherwise NK-resistant tumor cells
of different origins in vitro, as well as homing to ErbB2-
expressing tumors in vivo. Furthermore, antigen
specificity and selective cytotoxicity of these cells were
retained in vivo, resulting in antitumoral activity against
subcutaneous and intracranial glioblastoma xenografts in
NSG mice. Ongoing work now focuses on the develop-
ment of these cells for adoptive immunotherapy of
ErbB2-positive glioblastoma.
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